What you need to know about the forces reshaping our industry.


February 13, 2018

Trump announces new 'drug czar' nominee

Daily Briefing

    The White House on Friday announced that President Trump will nominate Jim Carroll, who currently serves as the White House's deputy chief of staff, to lead the Office of National Drug Control Policy (ONDCP).

    The Senate must confirm Carroll's nomination for ONDCP deputy and acting director.

    Carroll's background

    Prior to serving as deputy chief of staff, Carroll oversaw security clearance procedures in the White House counsel's office, The Hill reports. According to the Associated Press, Carroll also has previously worked at the Department of Justice, the Department of Treasury, and Ford Motor Company. The White House noted that Carroll also has worked as a commonwealth attorney in Virginia, where most of his cases related to drugs, and that Carroll worked with attorneys who had substance use disorders at the Virginia State Bar.


    White House press secretary Sarah Huckabee Sanders said officials "have full confidence in [Carroll] to lead ONDCP to make significant strides in combatting the opioids crisis, reducing drug use, and coordinating U.S. drug policy," adding, "Fighting the opioid crisis and drug addiction is a priority for [the Trump] administration" (Greenwood, The Hill, 2/9; Vavra, Axios, 2/9; MacDonald, FierceHealthcare, 2/12; Associated Press, 2/10; Politico, 2/9; Beech, Reuters, 2/9).

    Next: How to combat the opioid epidemic

    Opioid misuse and abuse is one of the most pressing public health issues in the U.S., and hospitals and health systems are on the front lines. Currently, most health systems focus their opioid management efforts on select medical specialties.

    This report outlines three imperatives to guide hospitals and health systems in their efforts to reduce the impact of inappropriate opioid prescribing and misuse.

    Get the Report

    Have a Question?


    Ask our experts a question on any topic in health care by visiting our member portal, AskAdvisory.